Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study.

Nat Commun · 2025 · PMC12589542 · PMID 41193416

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although not statistically significant, both PPV-06 groups showed a trend towards improvement compared to the placebo (Supplementary Figs. 3 , 4), especially in the Quality of Life and Symptoms subscales.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.